



The time has come to limit the placebo period in rheumatoid arthritis trials to 3 months: a systematic comparison of 3- and 6-month response rates in trials of biological agents

M Boers

► Additional data are published online only at <http://ard.bmj.com/content/vol69/issue1>

Correspondence to: Professor M Boers, Department of Epidemiology and Biostatistics, VU University Medical Centre, PK 6Z 165, PO Box 7057, 1007 MB Amsterdam, The Netherlands; eb@vumc.nl

Accepted 3 September 2009
Published Online First
22 September 2009

ABSTRACT

Background: Most registration trials in rheumatoid arthritis (RA) include a placebo arm in the setting of an incomplete response to disease-modifying antirheumatic treatment (DMARD-IR). A minimum duration of 6 months is required despite serious methodological and ethical shortcomings.

Objective: To study whether a 3-month placebo period is sufficient to prove efficacy.

Methods: Meta-analysis of placebo- or active control trials of biological agents in DMARD-IR RA, comparing the contrast in ACR response between experimental and control groups at 3 and 6 months.

Results: Twenty trials yielded 15 placebo and 18 active control contrasts (>10 000 patients). At 3 months active treatment showed a highly significant contrast with placebo for ACR20 and ACR50 in every instance. As all groups improved further the mean contrast at 6 months was unchanged. For ACR70 the contrast was clearly greater at 6 months owing to further improvement only in the experimental groups. In active control trials contrasts were smaller, and for ACR50 and ACR70 these decreased somewhat owing to "catch-up" responses in the control groups.

Conclusion: The placebo phase of registration trials for RA can be limited to 3 months. An accompanying viewpoint proposes that patients receiving placebo should then be switched to standard of care, allowing a more valid and comprehensive assessment, including safety.

Randomised placebo-controlled trials are required for most new drug applications. In rheumatoid arthritis (RA), placebo is added to background antirheumatic disease-modifying treatment continued in the setting of an incomplete response (DMARD-IR). A minimum of 6 months' duration has been required by regulatory agencies, although some trials have continued for a year or longer.

In a previous article I have outlined the many disadvantages of this design.¹ These include both ethical considerations and problems that jeopardise validity such as the definition of inadequate response, and selective dropout in the placebo group.

To see whether the placebo phase can be shortened this study compared the response rates at 3 and 6 months in a large dataset of trials of biological agents.

METHODS

In the context of an indirect comparison meta-analysis between tocilizumab and other biological

agents^{1a} the literature was searched for trials of currently licensed and commonly used biological agents in patients with moderate to severe RA who had an incomplete response to DMARDs. To be eligible for the current review, trial treatment had to be constant over 6 months and data on ACR20, ACR50, ACR70 response at both 3 and 6 months had to be available. Where necessary, response rates at 3 months were extracted from figures in the published report. Tocilizumab data was available from Roche clinical reports. Of these, three trials have now been fully published,²⁻⁴ one is available online,⁵ and one is only available in abstract form.⁶ Details of the search and data extraction strategy are available online (Appendix 1).

Trial contrasts were categorised as active control or placebo control, depending on whether or not the control group received treatment expected to work (on top of any background DMARD treatment). Several trials studied more than two groups: mostly placebo and different doses of the experimental drug. In these cases the contrast between placebo and the highest dose (or combination) was included in the placebo control part of the analysis, and the contrast between the active arms in the active control part. Thus the most active treatment arm was used twice. In one active control trial⁷ the least active treatment arm (methotrexate only) was used twice in the active control part of the analysis: once in the contrast with etanercept, and once in the contrast with etanercept plus methotrexate. No statistical adjustments were made for repeated comparisons.

The ratio of each ACR (20, 50, 70) response rate between control and experimental groups was summarised separately for the placebo and active control contrasts, by weighted Mantel-Haenszel random effect risk ratios (RevMan v 5 for Mac, Cochrane collaboration: <http://www.cochrane.org>). This risk ratio expresses the "risk" of response in the experimental group given the response in the control group.

Risk ratios of responses at 3 and 6 months were then compared in a stratified analysis, applying the same weights as in the first step. Finally, for the placebo trials sample size calculations were performed for a range of plausible response rates in the experimental groups.

RESULTS

The search identified 714 potentially relevant studies. Of these, 650 studies did not meet

Table 1 Characteristics of included studies (more details in online supplementary table 1)

Source, year ref	Sample size	Patient treatment history	Compared interventions	Contrasts used		Background treatment	Disease duration (years)	HAQ	Swollen joint count
				Placebo	Active				
<i>Placebo control</i> Smolen, 2008 ²	623	MTX-IR	3. Tcz 8 mg/kg IV/4 weeks vs 2. Tcz 4 mg/kg IV/4 weeks vs 1. Placebo	1 vs 3	2 vs 3	MTX	7.6	1.57	20
Genovese, 2008 ⁴	1216	DMARD-IR	2. Tcz 8 mg/kg IV/4 weeks vs 1. Placebo	1 vs 2		DMARD	9.8	1.50	19
Kremer, 2008 ⁶	1196	MTX-IR	3. Tcz 8 mg/kg IV/4 weeks vs 2. Tcz 4 mg/kg IV/4 weeks vs 1. Placebo	1 vs 3	2 vs 3	MTX	9.2	1.50	17
Weinblatt, 2003 ⁸	271	MTX-IR	4. Ada 80 mg SC/2 weeks vs 3. Ada 40 mg SC/2 weeks vs 2. Ada 20 mg SC/2 weeks vs 1. Placebo	1 vs 4	2 vs 3	MTX	12.3	1.57	17
Furst, 2003 ⁹	636	DMARD-IR	2. Ada 40 mg/2 weeks SC vs 1. Placebo	1 vs 2		Standard antirheumatic treatment	10.4	1.4	21
Van de Putte, 2004 ¹⁰	544	DMARD-IR	5. Ada 40 mg/2 weeks SC vs 4. Ada 40 mg/week SC vs 3. Ada 20 mg/2 weeks SC vs 2. Ada 20 mg/week SC vs 1. Placebo	1 vs 5	2 vs 3 4 vs 5	Usual concomitant treatment	10.9	1.86	20
Keystone, 2004 ¹¹	619	MTX-IR	3. Ada 40 mg/2 weeks SC vs 2. Ada 20 mg/2 weeks SC vs 1. Placebo	1 vs 3	2 vs 3	MTX	11.0	1.46	19
Weinblatt, 1999 ¹²	89	MTX-IR	2. Etan 25 mg/2 weeks SC vs 1. Placebo	1 vs 2		MTX	13.0	1.5	18
Combe, 2006 ¹³	254	SSZ-IR	3. Etan 25 mg SC/2 weeks + SSZ 2-3 g/day vs 2. Etan 25 mg SC/2 weeks vs 1. SSZ 2-3 g/day	1 vs 3	2 vs 3	None	6.4	1.63	19
Moreland, 1999 ¹⁴	234	DMARD-IR	3. Etan 25 mg/2 weeks SC vs 2. Etan 10 mg/2 weeks SC vs 1. Placebo	1 vs 3	2 vs 3	None	12.0	1.67	25

Table 1 Continued

Source, year ref	Sample size	Patient treatment history	Compared interventions	Contrasts used		Background treatment	Disease duration (years)	HAQ	Swollen joint count
				Placebo	Active				
Schiff, 2008 ¹⁵	431	MTX-IR	3. Ifx 3 mg/kg/8 weeks IV vs 2. Aba 10 mg/kg/month IV vs 1. Placebo	*	2 vs 3	MTX	7.9	1.77	20
Kremer, 2003 ¹⁶	339	MTX-IR	3. Aba 10 mg/kg/month IV vs 2. Aba 2 mg/kg/month IV vs 1. Placebo	1 vs 3	2 vs 3	MTX	9.4	1.00	21
Kremer, 2006 ¹⁷	652	MTX-IR	2. Aba 10 mg/kg/month IV vs 1. Placebo			MTX	8.7	NR	NR
Emery, 2006 ¹⁸	465	DMARD including biological agents-IR	3. Rtx 2 × 1.0 g IV in 2 weeks vs 2. Rtx 2 × 0.5 g IV in 2 weeks vs 1. Placebo	1 vs 3	2 vs 3	MTX	10.4	1.73	22
Cohen, 2006 ¹⁹	499	aTNF-IR	2. Rtx vs 1. Placebo	1 vs 2		MTX	11.9	1.9	23
Emery, 2008 ³	489	aTNF-IR	3. Tcz 8 mg/kg IV/4 weeks vs 2. Tcz 4 mg/kg IV/4 weeks vs 1. Placebo	1 vs 3	2 vs 3	MTX	11.6	1.7	19
<i>Active control</i> Jones, 2009 ⁵	572	No MTX in prev 6 months	2. Tcz 8 mg/kg IV/4 weeks vs 1. MTX		1 vs 2	None	9.8	1.6	19
Bathon 2000 ²⁰	622	No MTX in prev 6 months	3. Etan 25 mg/2 weeks SC vs 2. Etan 10 mg/2 weeks SC vs 1. MTX		1 vs 3 2 vs 3	None	1.0	NR	NR
Johnsen, 2006 ²¹	77	Failed ≥ 1 DMARD	2. Etan 50 mg/2 weeks SC vs 1. Etan 25 mg/2 weeks SC		1 vs 2	None	13.8	1.7	22
Klareskog, 2004 ⁷	686	DMARD-IR	3. Etan 25 mg/2 weeks SC + MTX vs 2. Etan 25 mg/2 weeks SC vs 1. MTX		1 vs 3 2 vs 3	None	6.6	1.7	23

*The report was incomplete for the placebo results.
Aba, abatacept; Ada, adalimumab; aTNF, anti-tumour necrosis factor; DMARD, disease-modifying antirheumatic drug; Etan, etanercept; HAQ, Health Assessment Questionnaire; Ifx, infliximab; IR, inadequate response; IV, intravenously; MTX, methotrexate; NR, not reported; Rtx, rituximab; SC, subcutaneously; SSZ, sulfasalazine; Tcz, tocilizumab.




Figure 1 Matrix plot describing ACR20, ACR50 and ACR70 responses (left y axis) at 3 and 6 months, for placebo and active controlled trials. Light bars, control group; dark bars, experimental group. The mean risk ratio with 95% confidence intervals and its change between 3 and 6 months is shown as connected dots (right y axis).

inclusion criteria. Five tocilizumab studies were added yielding a total of 69 studies potentially eligible for this review. Forty-nine had to be excluded after full-text review, yielding a final study set of 20 trials: 16 placebo and four active control trials on 10 514 patients.²⁻²¹ Full results of the study selection are available online. From the 20 included trials, 15 placebo and 18 active contrasts were extracted: in one three-arm trial, the placebo responses at 3 months were not available from the publication.¹⁵ Most patients included in the trials had severe, active and longstanding RA (table 1; more details in online supplementary table 1).

In general, responses were higher at 6 than at 3 months, but this was true for both control and experimental groups (table 2, fig 1). In placebo trials at both 3 and 6 months the contrasts (ie, differences between placebo and experimental groups) were all highly significant for ACR20 and ACR50 levels. For these response cut-off points the mean contrast did not change significantly between 3 and 6 months, marginally increasing for ACR20 and respectively decreasing for ACR50 (fig 1, table 2). Heterogeneity in these comparisons was evident from the range in the ratio of contrasts in individual trials: from 0.4 (3 months better) to 1.9 (6 months better).

Table 2 Pooled response rates; contrasts between treatment groups for placebo and active control trials expressed as risk ratios at 3 and 6 months; and the contrast (ratio of risk ratios) between 6 and 3 months.

	Response rate		Risk ratio* Mean (95% CI)	p Value
	Control	Experimental		
<i>Placebo control</i>				
ACR20				
3 Months	0.26	0.55	2.1 (1.9 to 2.3)	<0.001
DMARD-IR†	0.28	0.57	2.0 (1.8 to 2.3)	<0.001
TNF-IR‡	0.18	0.47	2.6 (2.1 to 3.3)	<0.001
6 Months	0.28	0.59	2.3 (1.9 to 2.8)	<0.001
DMARD-IR	0.30	0.61	2.1 (1.8 to 2.5)	<0.001
TNF-IR	0.14	0.51	3.6 (2.1 to 6.2)	<0.001
6 vs 3 Months			1.1 (1.0 to 1.2)	0.13
DMARD-IR			1.0 (0.9 to 1.2)	0.36
TNF-IR			1.4 (1.0 to 2.0)	0.08
ACR50				
3 Months	0.07	0.28	3.8 (3.3 to 4.4)	<0.001
DMARD-IR	0.07	0.29	3.7 (3.2 to 4.4)	<0.001
TNF-IR	0.05	0.23	4.5 (2.1 to 9.5)	<0.001
6 Months	0.10	0.36	3.6 (3.1 to 4.3)	<0.001
DMARD-IR	0.10	0.37	3.4 (2.9 to 4.0)	<0.001
TNF-IR	0.04	0.28	6.1 (3.7 to 10.1)	<0.001
6 vs 3 Months			0.9 (0.8 to 1.1)	0.42
DMARD-IR			0.9 (0.8 to 1.0)	0.12
TNF-IR			1.4 (0.9 to 2.0)	0.14
ACR70				
3 Months	0.02	0.11	4.1 (3.1 to 5.3)	<0.001
DMARD-IR	0.02	0.11	4.4 (3.3 to 5.8)	<0.001
TNF-IR	0.02	0.07	5.2 (0.3 to 95.4)	0.27
6 Months	0.03	0.18	5.8 (4.5 to 7.4)	<0.001
DMARD-IR	0.03	0.18	5.6 (4.3 to 7.3)	<0.001
TNF-IR	0.01	0.12	10.6 (3.9 to 29.2)	<0.001
6 vs 3 Months			1.4 (1.1 to 2.0)	0.02
DMARD-IR			1.4 (1.1 to 1.7)	0.001
TNF-IR			1.6 (0.1 to 29.3)	0.75
<i>Active control</i>				
ACR20				
3 Months	0.53	0.59	1.1 (1.1 to 1.2)	<0.001
6 Months	0.56	0.62	1.1 (1.0 to 1.2)	0.003
6 v 3 Months			1.0 (1.0 to 1.0)	0.30
ACR50				
3 Months	0.24	0.31	1.3 (1.1 to 1.4)	<0.001
6 Months	0.32	0.39	1.2 (1.1 to 1.3)	<0.001
6 v 3 Months			0.9 (0.9 to 1.0)	0.02
ACR70				
3 Months	0.08	0.12	1.5 (1.1 to 1.8)	0.002
6 Months	0.15	0.21	1.4 (1.3 to 1.6)	<0.001
6 v 3 Months			1.0 (0.9 to 1.0)	0.40

*Risk ratio, the risk of a response in the experimental group versus that in the control group; and the ratio of risk ratios at 6 versus 3 months. Results >1 indicate a greater contrast between the treatment groups at 6 months.

†DMARD-IR, patients with an incomplete response to disease-modifying drugs.

‡TNF-IR, patients with an incomplete response to anti-tumour necrosis factor agents.

For ACR70 the contrasts in response were clearly higher at 6 months: at 3 months the contrast between placebo and experimental groups was not significant in four out of 15 trials, decreasing to one out of 15 at 6 months. The “risk” of an ACR70 response on experimental compared with placebo treatment increased from 4.1 at 3 months to 5.8 at 6 months, a 40% increase (p = 0.02; table 2). This was mainly due to an

increase of patients meeting ACR70 only in the experimental groups. Finally, in the subgroup of (only two) trials in patients with an incomplete response to tumour necrosis factor contrasts were generally higher, with numerically higher responses at 6 than at 3 months. The small number of trials for each individual drug or drug class precluded meaningful comparisons between them.

As expected, responses in active control groups were much higher than those seen in placebo, resulting in a correspondingly smaller contrast with the experimental groups. For ACR20 the contrasts did not change significantly between 3 and 6 months. For ACR50 and ACR70 the contrast actually decreased somewhat (significant for ACR50), mostly because the response rate in the control groups increased more than that in the experimental groups—that is, a “catch-up” response.

Calculations for the placebo setting suggested sample sizes for both ACR20 and ACR50 are well below 100 patients per group for a range of plausible response rates (supplementary data in online Appendix 2 and supplementary figure to Appendix 2).

DISCUSSION

This study demonstrates that for currently available biological agents, a 3-month placebo phase is sufficient to demonstrate efficacy in signs and symptoms of RA.

Although a broad range of large key trials was included, many more could not be considered simply because the trial report was incomplete. As recently recommended by EULAR, all trial reports should include the results of the RA core set as well as ACR and EULAR response criteria at key time points.²² Editors can easily facilitate this by allowing publication of web-only material. However, the principal finding need not be demonstrated in all published trials to be valid. Even the current selection included trials that “benefited” from a longer placebo phase. Irrelevant benefit, I would argue as in all trials the difference at 3 months between active and placebo was highly significant for both ACR20 and ACR50 anyway, and in most this also applied to ACR70. Trials with 100 patients/group have over 90% power to show such differences in ACR20 and ACR50.

The requirement for 6 months’ stable treatment suggests that the results are not directly applicable to some “tight control” strategies of treatment that require switching or modifying treatment when an adequate response is not seen within 3 months. However, these trials are going to be restricted to using 3-month responses exclusively anyway. The study results do suggest that most current (rapidly acting) agents still need 6 months to develop their full effect. So registration trials should run for at least 6 months, but only 3 months of these need to be a comparison against placebo. As explained in the accompanying viewpoint in this issue, this opens the way to novel trial designs in which placebo patients are mandatorily switched to standard treatment after 3 months, or re-randomised to standard versus experimental treatment (*see article on page 4*).²³ Such designs create new complexities but also produce data comparing the new drug with standard active treatment early in the development phase. Imagine such data being available to the clinician at the time of registration of the new drug! For active control studies, although much information can be gathered in first 3 months, there is little or no justification for a 3-month study period in the context of a chronic disease usually requiring lifelong treatment.

There are concerns that go beyond the demonstration of short-term efficacy. Authorities and doctors are also interested in the full extent and the durability of effect, as well as safety. While not dealt with by the current study, a recommendation to limit the placebo phase to 3 months need not affect the data collection necessary to study these issues. Once separation from placebo is demonstrated, both full effect and durability can even be documented by a within-group comparison (change from baseline) in the experimental group continuing to receive treatment. For safety, the current practice of comparison with a depleted placebo group is probably less valid than a

comparison with a group that received proper treatment after 3 months of placebo.

For structural damage, current guidelines require trials of 1 or 2 years before a label can be given for a protective effect. In this context all the disadvantages of long placebo periods apply with respect to the validity of the comparisons being made. Data are available suggesting that a difference in damage progression can be demonstrated at 3 months in reasonable sample sizes (about 100 patients per group).²⁴ Again, both full effect and durability of effect can then be demonstrated by within-group comparisons and comparisons with a placebo group that switches to proper treatment after 3 months.

In conclusion, a 3-month placebo phase is sufficient to demonstrate efficacy in the treatment of signs and symptoms of RA. I propose that placebo patients should then be switched to standard of care, allowing a more valid and comprehensive assessment including safety.²⁵

Acknowledgements: I am grateful to Neil Winfield of Roche Laboratories, Nutley, USA for helpful comments; Adrian Kielhorn, F Hoffmann-La Roche, Basel, Switzerland for help in collecting the data; and F Hoffmann-La Roche, Basel, Switzerland for allowing use of their dataset.

Competing interests: None.

Provenance and peer review: Not commissioned; externally peer reviewed.

REFERENCES


1. **Boers M.** Add-on or step-up trials for new drug development in rheumatoid arthritis: a new standard? *Arthritis Rheum* 2003;**48**:1481–3.
- 1a. **Bergman GJD, Hochberg M, Boers M, et al.** Indirect comparison of tocilizumab with other biologic agents in patients with rheumatoid arthritis and an inadequate response to DMARDs. *Semin Arthritis Rheum* 2010;in press.
2. **Smolen JS, Beaulieu A, Rubbert-Roth A, et al.** Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. *Lancet* 2008;**371**:987–97.
3. **Emery P, Keystone E, Tony HP, et al.** IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. *Ann Rheum Dis* 2008;**67**:1516–23.
4. **Genovese MC, McKay JD, Nasonov EL, et al.** Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. *Arthritis Rheum* 2008;**58**:2968–80.
5. **Jones G, Sebba A, Gu J, et al.** Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. *Ann Rheum Dis* Published Online First: 17 March 2009. doi:10.1136/ard.2008.105197.
6. **Kremer JM, Fleischman RM, Halland A, et al.** Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to methotrexate: the LITHE Study, 2008:L14 (abstract). Available at <http://acr.confex.com/acr/2008/webprogram/Paper3479.html> (accessed 30 August 2009).
7. **Klareskog L, van der Heijde D, de Jager JP, et al.** Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. *Lancet* 2004;**363**:675–81.
8. **Weinblatt ME, Keystone EC, Furst DE, et al.** Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. *Arthritis Rheum* 2003;**48**:35–45.
9. **Furst DE, Schiff MH, Fleischmann RM, et al.** Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). *J Rheumatol* 2003;**30**:2563–71.
10. **van de Putte LB, Atkins C, Malaise M, et al.** Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. *Ann Rheum Dis* 2004;**63**:508–16.
11. **Keystone EC, Kavanaugh AF, Sharp JT, et al.** Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. *Arthritis Rheum* 2004;**50**:1400–11.
12. **Weinblatt ME, Kremer JM, Bankhurst AD, et al.** A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. *N Engl J Med* 1999;**340**:253–9.

13. **Combe B**, Codreanu C, Fiocco U, *et al*. Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. *Ann Rheum Dis* 2006;**65**:1357–62.
14. **Moreland LW**, Schiff MH, Baumgartner SW, *et al*. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. *Ann Intern Med* 1999;**130**:478–86.
15. **Schiff M**, Keiserman M, Coddling C, *et al*. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. *Ann Rheum Dis* 2008;**67**:1096–103.
16. **Kremer JM**, Westhovens R, Leon M, *et al*. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4lg. *N Engl J Med* 2003;**349**:1907–15.
17. **Kremer JM**, Genant HK, Moreland LW, *et al*. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. *Ann Intern Med* 2006;**144**:865–76.
18. **Emery P**, Fleischmann R, Filipowicz-Sosnowska A, *et al*. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. *Arthritis Rheum* 2006;**54**:1390–400.
19. **Cohen SB**, Emery P, Greenwald MW, *et al*. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. *Arthritis Rheum* 2006;**54**:2793–806.
20. **Bathon JM**, Martin RW, Fleischmann RM, *et al*. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. *N Engl J Med* 2000;**343**:1586–93.
21. **Johnsen AK**, Schiff MH, Mease PJ, *et al*. Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study. *J Rheumatol* 2006;**33**:659–64.
22. **Hoes JN**, Jacobs JW, Boers M, *et al*. EULAR evidence based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. *Ann Rheum Dis* 2007;**66**:1560–7.
23. **Boers M**. A new design for registration trials in rheumatoid arthritis allowing secondary head-to-head comparisons with standard of care treatment including biologicals. *Ann Rheum Dis* 2010;**69**:4–6.
24. **Bruynesteyn K**, Landewe R, van der Linden S, *et al*. Radiography as primary outcome in rheumatoid arthritis: acceptable sample sizes for trials with 3 months' follow up. *Ann Rheum Dis* 2004;**63**:1413–18.

Submit an eLetter, and join the debate

eLetters are a fast and convenient way to register your opinion on topical and contentious medical issues. You can find the “submit a response” link alongside the abstract, full text and PDF versions of all our articles. We aim to publish swiftly, and your comments will be emailed directly to the author of the original article to allow them to respond. eLetters are a great way of participating in important clinical debates, so make sure your voice is heard.

sample size per group



sample size per group

